

# CITATION REPORT

List of articles citing

Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide

DOI: 10.1161/01.CIR.93.11.1963  
Circulation, 1996, 93, 1963-9.

**Source:** <https://exaly.com/paper-pdf/86224753/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
518	Metabolic, functional, and haemodynamic staging for CHF?. <b>1996</b> , 348, 1530-1		34
517	Letter. <b>1996</b> , 112, 1129		
516	Neuroendocrine activation after myocardial infarction: causes and consequences. <b>1996</b> , 76, 53-9		8
515	Brain natriuretic peptide predicts mortality in the elderly. <b>1997</b> , 77, 264-7		125
514	Wasting as independent risk factor for mortality in chronic heart failure. <b>1997</b> , 349, 1050-3		1033
513	The natriuretic-peptide family. <b>1997</b> , 349, 1307-10		183
512	Analytical Agreement and Clinical Correlates of Plasma Brain Natriuretic Peptide Measured by Three Immunoassays in Patients with Heart Failure. <b>1997</b> , 43, 2439-2440		6
511	Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. <b>1998</b> , 28, 636-42		67
510	Plasma natriuretic peptides as indicators of left ventricular remodeling after myocardial infarction. <b>1998</b> , 64, 153-60		9
509	Biochemical detection of systolic dysfunction. <b>1998</b> , 351, 1063; author reply 1063-4		4
508	Natriuretic peptides and contractile reserve in dilated cardiomyopathy. <b>1998</b> , 352, 487-8		3
507	Biochemical detection of left-ventricular systolic dysfunction. <b>1998</b> , 351, 9-13		853
506	Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction. <b>1998</b> , 31, 399-403		43
505	Elevated B-type natriuretic peptide levels after anthracycline administration. <b>1998</b> , 136, 362-3		136
504	Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. <b>1998</b> , 21, 170-9		156
503	Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. <b>1998</b> , 135, 825-32		611
502	Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. <b>1998</b> , 135, 914-23		201

501	The pathophysiology of advanced heart failure. <b>1998</b> , 135, S216-30	63
500	Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. <b>1998</b> , 135, 21-8	180
499	The role of the neurohormonal system in heart failure. <b>1998</b> , 79, S17-23	7
498	Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. <b>1998</b> , 275, H1200-8	8
497	Plasma brain natriuretic peptide--an independent predictor of cardiovascular mortality in acute heart failure. <b>1999</b> , 1, 59-65	60
496	Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. <b>1999</b> , 81, 114-20	116
495	Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. <b>1999</b> , 81, 121-7	43
494	Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. <b>1999</b> , 134, 437-44	81
493	Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. <b>1999</b> , 84, 741-4, A9	39
492	The pathophysiology of advanced heart failure. <b>1999</b> , 28, 87-101	43
491	Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. <b>1999</b> , 69, 5-14	37
490	Brain natriuretic peptide as a marker of cardiac involvement in hypertension. <b>1999</b> , 69, 169-77	27
489	Stability of brain natriuretic peptide (BNP) in human blood samples. <b>1999</b> , 285, 169-72	36
488	Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. <b>1999</b> , 138, 1126-32	196
487	Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. <b>1999</b> , 138, 654-62	43
486	Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure?. <b>1999</b> , 116, 861-7	16
485	Atrial natriuretic peptide and the development of congestive heart failure in the oldest old: a seven-year prospective study. <b>1999</b> , 47, 407-11	3
484	Heart failure as a metabolic problem. <b>1999</b> , 1, 127-31	20

483	Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. <b>1999</b> , 61, 523-9	72
482	Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. <b>2000</b> , 18, 1121-8	114
481	Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. <b>2000</b> , 50, 15-20	12
480	N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males. <b>2000</b> , 247, 699-708	10
479	Risk stratification after acute myocardial infarction in the reperfusion era. <b>2000</b> , 42, 273-309	37
478	Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. <b>2000</b> , 86, 417-21	43
477	Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. <b>2000</b> , 23, 921-7	27
476	Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac. <b>2000</b> , 278, E1115-23	30
475	Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. <b>2000</b> , 278, H1500-6	75
474	Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. <b>2000</b> , 41, 205-14	19
473	Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. <b>2000</b> , 38, 519-23	31
472	Practical implications of current natriuretic peptide research. <b>2000</b> , 1, 304-15	10
471	Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. <b>2000</b> , 83, 278-82	67
470	Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. <b>2000</b> , 108, 627-33	28
469	Intérêt clinique du BNP (brain natriuretic peptide) dans l'insuffisance cardiaque : revue de la littérature et expérience personnelle. <b>2000</b> , 15, 161-168	
468	Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. <b>2000</b> , 301, 19-30	76
467	Circulating interleukin-6 significantly correlates to thyroid hormone in acute myocardial infarction but not in chronic heart failure. <b>2000</b> , 23, 509-14	6
466	Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. <b>2000</b> , 6, 201-7	45

465	Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. <b>2000</b> , 36, 1202-9	438
464	High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. <b>2000</b> , 36, 1587-93	341
463	Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. <b>2000</b> , 35, 714-21	161
462	Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. <b>2001</b> , 7, 322-8	21
461	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. <b>2001</b> , 37, 1228-33	285
460	Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. <b>2001</b> , 37, 1781-7	282
459	The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. <b>2001</b> , 345, 1014-21	1046
458	Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. <b>2001</b> , 141, 751-8	124
457	Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. <b>2001</b> , 142, 1056-64	31
456	Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. <b>2001</b> , 305, 181-6	38
455	The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. <b>2001</b> , 39, 571-88	176
454	Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. <b>2001</b> , 280, H368-76	29
453	Plasma and pericardial fluid natriuretic peptide levels in postinfarction ventricular dysfunction. <b>2001</b> , 3, 21-6	15
452	Cardiac natriuretic peptides--hope or hype?. <b>2001</b> , 26, 15-31	24
451	Effect of patency from coronary angioplasty during acute myocardial infarction on left ventricular remodeling and levels of natriuretic peptides later. <b>2001</b> , 88, 683-5	2
450	Usefulness of plasma brain natriuretic peptide after acute myocardial infarction in predicting left ventricular dilatation six months later. <b>2001</b> , 88, 890-3, A8	10
449	Are natriuretic peptides clinically useful as markers of heart failure?. <b>2001</b> , 38, 575-83	11
448	Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. <b>2001</b> , 86, 21-6	184

447	Differential secretion of atrial and brain natriuretic peptide in critically ill patients. <b>2001</b> , 93, 676-82	48
446	Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. <b>2001</b> , 86, 638-42	64
445	Amino-terminal pro-brain natriuretic peptide in normal and hypertensive pregnancy. <b>2001</b> , 20, 169-75	27
444	Nesiritide for Acute Decompensated Heart Failure. <b>2002</b> , 18, 295-304	
443	Clinical implications of cardiac (123)I-meta-iodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease. <b>2002</b> , 23, 795-801	8
442	Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver. <b>2002</b> , 122, 140-5	18
441	Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. <b>2002</b> , 66, 323-36	63
440	Antecedent hypertension and heart failure after myocardial infarction. <b>2002</b> , 39, 1182-8	75
439	Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. <b>2002</b> , 39, 1623-9	191
438	N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. <b>2002</b> , 40, 437-45	282
437	Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. <b>2002</b> , 40, 1596-601	157
436	Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. <b>2002</b> , 347, 161-7	2595
435	[Brain natriuretic peptide. Diagnostic value in heart failure]. <b>2002</b> , 55, 7-15	25
434	Molecular forms of human brain natriuretic peptide in plasma. <b>2002</b> , 316, 129-35	123
433	Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. <b>2002</b> , 143, 790-6	27
432	Atrial natriuretic factor as marker of myocardial compromise in Chagas disease. <b>2002</b> , 105, 139-43	13
431	Natriuretic peptides in the diagnosis of heart disease--first amongst equals?. <b>2002</b> , 84, 107-13	10
430	Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. <b>2002</b> , 86, 143-9; discussion 149-52	20

429	Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector. <b>2002</b> , 283, H1439-45	11
428	BNP and congestive heart failure. <b>2002</b> , 44, 293-321	142
427	Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. <b>2002</b> , 89, 463-5	133
426	Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. <b>2002</b> , 90, 496-500	37
425	Immune and neurohormonal pathways in chronic heart failure. <b>2002</b> , 8, 23-8, 48	23
424	Plasma C-reactive protein predicts left ventricular remodeling and function after a first acute anterior wall myocardial infarction treated with coronary angioplasty: comparison with brain natriuretic peptide. <b>2002</b> , 25, 112-6	14
423	Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. <b>2003</b> , 41, 532-45	29
422	B-type natriuretic peptide in ischemic heart disease. <b>2003</b> , 5, 271-7	9
421	Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. <b>2003</b> , 92, 1124-7	121
420	BNP and congestive heart failure. <b>2003</b> , 28, 264-311	8
419	Plasma N-terminal pro-brain natriuretic peptide in Type 1 diabetic patients with and without diabetic nephropathy. <b>2003</b> , 20, 535-9	26
418	Plasma brain natriuretic peptide levels increase in proportion to changes in pulmonary artery pressure in old-old persons. <b>2003</b> , 51, 891-3	2
417	Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics. <b>2003</b> , 27, 849-61	36
416	Myocardial velocity gradient reflects the severity of myocardial damage regardless of the presence or absence of mitral regurgitation. <b>2003</b> , 16, 246-53	8
415	Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. <b>2003</b> , 41, 1264-72	338
414	Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. <b>2003</b> , 41, 2280-7	157
413	Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. <b>2003</b> , 42, 728-35	304
412	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <b>2003</b> , 146, 729-35	47

411	Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. <b>2003</b> , 114, 25-30	55
410	The prognostic importance of anemia in patients with heart failure. <b>2003</b> , 114, 112-9	221
409	Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. <b>2003</b> , 114, 266-70	57
408	Brain natriuretic peptide: a marker for subclinical cardiovascular disease?. <b>2003</b> , 114, 329-30	3
407	Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. <b>2003</b> , 338, 107-15	254
406	Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. <b>2003</b> , 17, 172-7	60
405	B-type natriuretic peptide in cardiovascular disease. <b>2003</b> , 362, 316-22	825
404	Characterization of molecular forms of probrain natriuretic peptide in human plasma. <b>2003</b> , 334, 233-9	83
403	Exercise training without ventricular remodeling in patients with moderate to severe left ventricular dysfunction early after acute myocardial infarction. <b>2003</b> , 87, 237-44	30
402	Cardiac hormones as diagnostic tools in heart failure. <b>2003</b> , 24, 341-56	202
401	Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. <b>2003</b> , 22, 1037-45	21
400	New Biochemical Tools for Diagnosing Acute Coronary Syndromes. <b>2003</b> , 11, 519-540	1
399	Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. <b>2003</b> , 41, 164-8	17
398	Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. <b>2003</b> , 89, 871-4	63
397	NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. <b>2003</b> , 89, 150-4	137
396	Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. <b>2003</b> , 5, 481-8	49
395	Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. <b>2003</b> , 5, 499-506	81
394	B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. <i>Circulation</i> , <b>2003</b> , 108, 2987-92	16.7 186



393	Adrenomedullin induces direct (endothelium-independent) vasorelaxations and cyclic adenosine monophosphate elevations that are synergistically enhanced by brain natriuretic peptide in isolated rings of rat thoracic aorta. <b>2003</b> , 41, 849-55	8
392	Radioimmunoassay of natriuretic peptide type-B (BNP) in heart failure. <b>2003</b> , 24, 61-9	6
391	The Endocrine Heart: B-type Natriuretic Peptide as a Diagnostic and Therapeutic Agent in Cardiovascular Disease. <b>2003</b> , 13, 97-105	1
390	Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure. <b>2003</b> , 44, 713-24	12
389	Inhibition of L-type Ca <sup>2+</sup> current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. <b>2003</b> , 285, H2454-62	25
388	Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. <b>2004</b> , 50, 33-50	277
387	Natriuretic peptides, respiratory disease, and the right heart. <b>2004</b> , 126, 1330-6	119
386	Plasma brain natriuretic peptide in takotsubo cardiomyopathy. <b>2004</b> , 97, 599-607	74
385	Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. <b>2004</b> , 50, 1576-88	137
384	Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. <b>2004</b> , 90, 2073-9	50
383	N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). <b>2004</b> , 6, 335-41	77
382	Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. <b>2004</b> , 90, 97-8	22
381	NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. <b>2004</b> , 6, 343-50	71
380	Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. <b>2004</b> , 286, H1970-7	43
379	NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials. <b>2004</b> , 6, 319-25	38
378	Brain natriuretic peptide in the prediction of recurrence of angina pectoris. <b>2004</b> , 34, 79-84	18
377	Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. <b>2004</b> , 128, 38-43	51
376	Heart failure management in the emergency department observation unit. <b>2004</b> , 46, 465-85	13

375	Troponins in acute coronary syndromes. <b>2004</b> , 47, 177-88	37
374	B-type natriuretic Peptide and the right heart. <b>2004</b> , 9, 99-105	21
373	Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. <b>2004</b> , 6, 273-8	12
372	The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. <b>2004</b> , 37, 847-56	62
371	Science review: natriuretic peptides in critical illness. <b>2004</b> , 8, 342-9	41
370	Aplicaciones clínicas de la determinación plasmática del péptido natriurético auricular. <b>2004</b> , 28, 365-375	
369	Factores pronósticos en la insuficiencia cardíaca. <b>2004</b> , 30, 437-443	
368	Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. <b>2004</b> , 43, 757-63	92
367	Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. <b>2004</b> , 43, 764-70	232
366	B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. <b>2004</b> , 43, 1584-9	105
365	Urinary biopyrrins levels are elevated in relation to severity of heart failure. <b>2004</b> , 43, 1880-5	54
364	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. <b>2004</b> , 44, 335-9	171
363	Heart failure in the emergency department: is B-type natriuretic peptide a better prognostic indicator than clinical assessment?. <b>2004</b> , 44, 1334-6	
362	Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. <b>2004</b> , 44, 1988-95	270
361	Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. <b>2004</b> , 10, 310-5	24
360	Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. <b>2004</b> , 10, 490-5	60
359	Plasma natriuretic peptide levels and the risk of cardiovascular events and death. <b>2004</b> , 350, 655-63	1133
358	The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. <b>2004</b> , 340, 163-72	71

357	Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. <b>2004</b> , 346, 119-28	32
356	Clinical applications of B-type natriuretic peptides. <b>2004</b> , 15, 170-4	12
355	Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. <b>2004</b> , 14, 732-9	22
354	Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. <b>2004</b> , 147, 1078-84	190
353	Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure?. <b>2004</b> , 148, 349-55	15
352	Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. <b>2004</b> , 116, 509-16	46
351	Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. <b>2004</b> , 116, 517-23	27
350	Benefits of tai chi in chronic heart failure: body or mind?. <b>2004</b> , 117, 611-2	3
349	Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. <b>2004</b> , 23, 20-7	13
348	Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus. <b>2004</b> , 30, 381-6	9
347	Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. <b>2004</b> , 32, 1643-7	141
346	A-type and B-type natriuretic peptides in cardiac surgical procedures. <b>2004</b> , 98, 11-19	64
345	B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSIS TOOL IN CORONARY ARTERY BYPASS GRAFTING SURGERY. <b>2004</b> , 32, A10	
344	Clinical utility of biomarkers in myocardial injury. <b>2004</b> , 17, 49-55	7
343	Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. <b>2004</b> , 125, 652-68	74
342	N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. <b>2004</b> , 107, 309-16	38
341	Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. <b>2004</b> , 43, 1015-22	31
340	NT-proBNP: a marker for successful myocardial reperfusion in AMI patients treated with primary percutaneous coronary intervention. <b>2004</b> , 6, 749-52	2

339	B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. <b>2005</b> , 128, 21-9	57
338	Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). <b>2005</b> , 109, 69-74	33
337	Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. <b>2005</b> , 69, 654-8	27
336	Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. <b>2005</b> , 52, 353-62	25
335	Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. <b>2005</b> , 128, 288-95	106
334	Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. <b>2005</b> , 45, 573-80	73
333	Natriuretic peptides and the dialysis patient. <b>2005</b> , 18, 409-19	31
332	NT-proBNP in normoalbuminuric patients with Type 2 diabetes mellitus. <b>2005</b> , 22, 188-95	14
331	Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. <b>2005</b> , 22, 473-8	38
330	B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. <b>2005</b> , 95, 24-8	50
329	Comparison of the usefulness of Doppler-derived deceleration time versus plasma brain natriuretic peptide to predict left ventricular remodeling after mechanical revascularization in patients with ST-elevation acute myocardial infarction and left ventricular systolic dysfunction. <b>2005</b> , 95, 930-4	13
328	Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. <b>2005</b> , 48, 153-68	80
327	Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. <b>2005</b> , 91, 601-5	26
326	N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. <b>2005</b> , 352, 666-75	494
325	Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale. <b>2005</b> , 33, 612-9	9
324	Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. <b>2006</b> , 92, 735-40	21
323	Acutely decompensated congestive heart failure: new therapies for an old problem. <b>2005</b> , 3, 925-36	
322	Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. <b>2005</b> , 26, 241-9	81

321	N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure. <b>2005</b> , 3, 487-96	4
320	The comparison of amino-terminal probrain natriuretic peptide levels in preeclampsia and normotensive pregnancy. <b>2005</b> , 33, 121-4	41
319	Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. <b>2005</b> , 26, 250-6	15
318	B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. <b>2005</b> , 26, 234-40	87
317	Health gains by using natriuretic peptides in diagnosis, prognosis and treatment. <b>2005</b> , 240, 129-37	3
316	Using the emergency department clinical decision unit for acute decompensated heart failure. <b>2005</b> , 23, 569-88, viii	22
315	Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. <b>2005</b> , 240, 18-24	7
314	Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. <b>2005</b> , 123, 25-32	49
313	Fluorescence imaging microscopy of cellular markers in ischemic vs non-ischemic cardiomyopathy after left ventricular unloading. <b>2005</b> , 24, 454-61	5
312	Surgical ventricular remodeling for patients with clinically advanced congestive heart failure and severe left ventricular dysfunction. <b>2005</b> , 24, 2202-10	16
311	The prediction of in-hospital mortality by amino terminal pro-brain natriuretic peptide (NT-proBNP) levels and other independent variables in acutely ill patients with suspected heart disease. <b>2005</b> , 16, 195-199	4
310	Biology of natriuretic peptides and their receptors. <b>2005</b> , 26, 901-32	172
309	Natriuretic peptides as prognostic and diagnostic markers in Chagas disease. <b>2005</b> , 128, 203-10	9
308	Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia. <b>2005</b> , 150, 695-700	34
307	Evaluation and management of the acutely dyspneic patient: the role of biomarkers. <b>2005</b> , 23, 371-8	26
306	NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. <b>2005</b> , 11, S3-8	70
305	NT-ProBNP in non-ST-elevation acute coronary syndrome. <b>2005</b> , 11, S54-8	5
304	The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. <b>2005</b> , 11, S9-14	88

303	Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. <b>2005</b> , 11, S34-7	12
302	Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. <b>2005</b> , 11, 492-7	22
301	Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. <b>2005</b> , 46, 838-44	126
300	Markers of cardiac ischemia and inflammation. <b>2005</b> , 23, 491-501, vi	4
299	Clinical practice. Acute pulmonary edema. <b>2005</b> , 353, 2788-96	460
298	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. <b>2006</b> , 22, 393-7	22
297	Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. <b>2006</b> , 27, 47-72	747
296	Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. <b>2006</b> , 47, 52-60	136
295	Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. <b>2006</b> , 12, 66-72	94
294	Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease?. <b>2006</b> , 151, 712.e1-712.e7	28
293	Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. <b>2006</b> , 152, 927.e1-6	52
292	Serum biomarkers for heart failure. <b>2006</b> , 15, 144-9	19
291	B-type natriuretic peptide is an independent predictor for cardiovascular death in patients with no clinical signs of ventricular dysfunction after acute myocardial infarction. <b>2006</b> , 67, 1076-8	1
290	The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. <i>Biomarker Insights</i> , <b>2006</b> , 1, 117727190600100	3.5 0
289	B-type natriuretic peptide concentrations and myocardial dysfunction in critical illness. <b>2006</b> , 34, 151-63	4
288	Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. <b>2006</b> , 70, 1006-11	58
287	N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <b>2006</b> , 70, 163-8	21
286	Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. <b>2006</b> , 70, 447-52	36

285	Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. <b>2006</b> , 332, 186-97	33
284	Fonction endocrine du cŕ. <b>2006</b> , 1, 1-8	
283	Update on Cardiac Biomarkers. <b>2006</b> , 37, 597-605	3
282	Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients undergoing allogeneic bone marrow transplantation. <b>2006</b> , 11, 351-4	2
281	Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography. <b>2006</b> , 17, 255-9	8
280	CPAP results in a sustained decrease of NT-pro BNP in normotensive and hypertensive patients with obstructive sleep apnoea syndrome. <b>2006</b> , 10, 10-14	
279	Brain natriuretic peptide (nesiritide) in the treatment of heart failure. <b>2002</b> , 20, 27-36	15
278	Intraindividual temporal variance of biomarkers and the definition of individualized prognosis in cardiovascular patients. <b>2006</b> , 20, 383-6	11
277	Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. <b>2006</b> , 29, 405-10	20
276	NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. <b>2006</b> , 95, 23-30	37
275	Postmortem pericardial natriuretic peptides as markers of cardiac function in medico-legal autopsies. <b>2007</b> , 121, 28-35	45
274	Correlation between plasma brain natriuretic peptide concentration and lung thallium-201 uptake on exercise thallium perfusion images. <b>2006</b> , 21, 78-83	
273	Elevated BNP with normal systolic function in asymptomatic individuals at-risk for heart failure: a marker of diastolic dysfunction and clinical risk. <b>2006</b> , 175, 5-13	2
272	N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. <b>2006</b> , 97, 1151-6	23
271	Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function. <b>2006</b> , 98, 1322-8	22
270	Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. <b>2006</b> , 98, 1504-6	33
269	[The role of B type natriuretic peptide in the assessment of post myocardial infarction prognosis]. <b>2006</b> , 55, 264-70	1
268	Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. <b>2006</b> , 27, 1485-94	244

267	Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. <b>2006</b> , 6, 649-62	4
266	Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. <b>2006</b> , 8, 797-803	23
265	PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. <b>2006</b> , 290, H1740-6	30
264	Natriuretic peptides as a prognostic marker and therapeutic target in heart failure. <b>2006</b> , 92, 149-51	16
263	Serum chemical biomarkers of cardiac injury for nonclinical safety testing. <b>2006</b> , 34, 94-104	68
262	Effect of physical training on exercise capacity, gas exchange and N-terminal pro-brain natriuretic peptide levels in patients with chronic heart failure. <b>2006</b> , 13, 812-7	47
261	Natriuretic Peptides in Acute and Chronic Coronary Artery Disease. <b>2006</b> , 409-425	
260	Best evidence topic report. Brain natriuretic peptide as a potential marker of acute coronary syndromes. <b>2006</b> , 23, 403-7	7
259	Classification and Prognosis of Pulmonary Arterial Hypertension. <b>2006</b> , 66-82	1
258	Determining the cause of dyspnoea: linguistic and biological descriptors. <b>2006</b> , 3, 117-22	21
257	Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. <b>2007</b> , 9, 802-7	37
256	NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. <b>2007</b> , 9, 660-6	23
255	Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. <b>2007</b> , 30, 913-9	20
254	Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy. <b>2007</b> , 85, 790-9	38
253	Effects of an aging vascular model on healthy and diseased hearts. <b>2007</b> , 293, H1334-43	9
252	Plasma levels of B-type natriuretic Peptide in patients with unstable angina pectoris or acute myocardial infarction: prognostic significance and therapeutic implications. <b>2007</b> , 58, 269-74	4
251	Serum NT-proBNP concentrations in the early phase do not predict the severity of systolic or diastolic left ventricular dysfunction among patients with ST-elevation acute myocardial infarction. <b>2006</b> , 57, 686-93	2
250	B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. <b>2007</b> , 93, 1077-80	7



249	Atrial natriuretic peptide and related peptides. <b>2007</b> , 45, 1259-67	24
248	Cardiac natriuretic peptides after myocardial infarction: relationship with infarct size, left ventricular function and remodelling assessed by 99mTc-sestamibi gated-single photon emission tomography. <b>2007</b> , 45, 226-31	7
247	Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. <b>2007</b> , 131, 964-71	107
246	Can we use B-type natriuretic peptides to monitor patients with heart failure?. <b>2007</b> , 1, 349-53	
245	Screening and therapy of pulmonary hypertension in systemic sclerosis. <b>2007</b> , 19, 598-603	13
244	Prognostic value of reduced kidney function and anemia in patients with chronic heart failure. <b>2007</b> , 8, 909-16	7
243	Effects of cardiac resynchronization therapy on insulin-like growth factor-1 in patients with advanced heart failure. <b>2007</b> , 8, 917-22	
242	N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study. <b>2007</b> , 167, 483-9	17
241	NT-proBNP, IGF-I and survival in patients with chronic heart failure. <b>2007</b> , 17, 288-96	45
240	Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. <b>2007</b> , 26, 1033-9	10
239	B-type natriuretic peptide and assessment of jeopardised myocardium in acute myocardial infarction. <b>2007</b> , 114, 46-9	9
238	Ventricular endocrine and mechanical function following thrombolysis for acute myocardial infarction. <b>2007</b> , 117, 51-8	6
237	Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. <b>2007</b> , 120, 338-43	27
236	ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. <b>2007</b> , 122, 195-201	27
235	Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. <b>2007</b> , 121, 68-73	25
234	Circulating endothelial progenitor cells in congestive heart failure. <b>2007</b> , 119, 344-8	59
233	Prospective Clinical Evaluation of an ELISA B-Type Natriuretic Peptide Assay in the Diagnosis of Congestive Heart Failure in Dogs Presenting with Cough or Dyspnea. <b>2007</b> , 21, 243-250	58
232	Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. <b>2007</b> , 50, 205-14	177

231	Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. <b>2007</b> , 50, 1973-80	117
230	Utility of B-type Natriuretic Peptide in Patients with Acute Respiratory Distress Syndrome. <b>2007</b> , 62, 389	1
229	Brain natriuretic peptide detects cardiac abnormalities in mass screening. <b>2007</b> , 37, 257-62	14
228	Permanent and atrial-synchronized ventricular stimulation for clinically stable patients with normal or impaired left ventricular systolic function. <b>2007</b> , 30, 182-7	6
227	Role of natriuretic hormones in the diagnosis of patent ductus arteriosus in newborn infants. <b>2007</b> , 90, 363-365	2
226	Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure. <b>2007</b> , 22, 4-9	8
225	Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. <b>2008</b> , 41, 231-9	47
224	Takotsubo cardiomyopathy in acute ischemic stroke. <b>2008</b> , 64, 547-54	150
223	A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. <b>2008</b> , 41, 260-5	26
222	Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling. <b>2008</b> , 15, 644-54	3
221	N-terminal pro-brain natriuretic peptide in the elderly with myocardial infarction. <b>2008</b> , 31, 443-7	2
220	Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. <b>2008</b> , 31, 572-9	10
219	Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity. <b>2008</b> , 31, 701-8	26
218	Cardiac natriuretic peptides [hope or hype?]. <b>2008</b> , 26, 15-31	
217	Brain natriuretic peptides as biomarkers for atherosclerosis. <b>2008</b> , 11, 172-6	9
216	Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. <b>2008</b> , 178, 85-90	19
215	Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. <b>2008</b> , 51, 1857-64	73
214	Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. <b>2008</b> , 128, 244-9	18

213	The long-term prognostic value of multiple biomarkers following a myocardial infarction. <b>2008</b> , 123, 60-6	29
212	The effects of central arterial pressure and autonomic dysfunction on elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) in men with diabetes. <b>2008</b> , 2, 60	
211	Emerging Roles of Natriuretic Peptides and their Receptors in Pathophysiology of Hypertension and Cardiovascular Regulation. <b>2008</b> , 2, 210-26	50
210	Severe mitral regurgitation-relations between magnetic resonance imaging, echocardiography and natriuretic peptides. <b>2008</b> , 42, 48-55	5
209	Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. <b>2008</b> , 29, 2116-24	98
208	Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease. <b>2008</b> , 109, 249-57	5
207	Using Myocardial Imaging to Identify and Manage Subclinical Heart Disease in Diabetes Mellitus and Obesity. <b>2008</b> , 185-197	
206	B-type natriuretic peptides: prognostic markers in stable coronary artery disease. <b>2008</b> , 8, 217-25	18
205	Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: correlation with stroke severity. <b>2008</b> , 31, 1695-702	38
204	Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. <b>2008</b> , 36, S17-27	53
203	B-type natriuretic peptide (BNP) and proBNP: role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders. <b>2008</b> , 15, 150-6	9
202	Role of Neurohormones. <b>2008</b> , 345-366	
201	B-Type Natriuretic Peptide and Long-Term Prognosis in Low-Risk Patients With Unstable Angina. <b>2009</b> , 39, 26	
200	Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide. <b>2009</b> , 3, 465-81	11
199	Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. <b>2009</b> , 11, 444-52	114
198	Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. <b>2009</b> , 11, 832-9	41
197	Characterization of NT-proBNP in human urine. <b>2009</b> , 55, 1126-34	7
196	Brain natriuretic peptide levels in Kawasaki disease: a case report. <b>2009</b> , 51, 415-8	3

195	Effect of renal function loss on NT-proBNP level variations. <b>2009</b> , 42, 1091-8	13
194	N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. <b>2009</b> , 42, 1500-3	7
193	N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. <b>2009</b> , 32, 447-53	15
192	NT-proBNP on admission for early risk stratification in STEMI patients submitted to PCI. Relation with extension of STEMI and inflammatory markers. <b>2009</b> , 132, 84-9	49
191	N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. <b>2009</b> , 133, 173-8	25
190	[Prognostic value of B-type natriuretic peptide in unstable angina and non-ST-elevation myocardial infarction]. <b>2009</b> , 133, 569-73	0
189	Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. <b>2009</b> , 54, 1099-106	104
188	Natriuretic Peptides and Cardiovascular Regulation. <b>2009</b> , 219-237	
187	Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. <b>2009</b> , 30, 314-20	82
186	Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. <b>2009</b> , 338, b1605	37
185	N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. <b>2009</b> , 117, 31-9	38
184	Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes. <b>2009</b> , 20, 225-9	3
183	Surgical ventricular restoration: an operation to reverse remodeling - the basic science (part I). <b>2009</b> , 5, 343-9	2
182	Cardiac biomarkers - the old and the new: a review. <b>2010</b> , 21, 244-56	35
181	Influence of low-grade inflammation on plasma B-type natriuretic peptide levels. <b>2010</b> , 49, 2659-68	10
180	Irrelevant B-type natriuretic peptide levels in patients with mechanical prostheses in the mitral position presenting with congestive heart failure. <b>2010</b> , 74, 1584-90	1
179	Significance of B-type natriuretic peptide measurement in patients with chronic kidney disease. <b>2010</b> , 74, 632-3	1
178	Biomarkers in heart failure: a clinical review. <b>2010</b> , 15, 251-73	19

177	The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. <b>2010</b> , 59, 7-13	13
176	Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. <b>2010</b> , 39, 278-84	18
175	Biomarkers in acute myocardial infarction. <b>2010</b> , 8, 34	142
174	Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. <b>2010</b> , 106, 1011-5	33
173	Evaluation of N-terminal prohormone B-type natriuretic Peptide in patients with acute coronary syndromes and percutaneous coronary intervention. <b>2010</b> , 12, 861-8	
172	Comparison of N-terminal pro B-natriuretic Peptide and echocardiographic indices in patients with mitral regurgitation. <b>2010</b> , 4, 111-6	1
171	Long-term prognostic value of mitral regurgitation in acute coronary syndromes. <b>2010</b> , 96, 1803-8	16
170	B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. <b>2010</b> , 55, 1189-1196	61
169	Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients. <b>2010</b> , 140, 336-43	10
168	The relationship between tumor necrosis factor- $\beta$ brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. <b>2010</b> , 141, 39-43	51
167	Relation of B-type natriuretic peptide (BNP) and infarct size as assessed by contrast-enhanced MRI. <b>2010</b> , 144, 53-8	16
166	Relationship of natriuretic peptide and transthoracic echocardiographic findings in 135 subjects with muscular dystrophy. <b>2010</b> , 145, 506-14	
165	Circulating levels of stress associated peptide Urocortin in heart failure patients. <b>2010</b> , 31, 354-6	13
164	Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. <b>2011</b> , 58, 1705-14	67
163	Biochemical markers in acute coronary syndrome. <b>2011</b> , 412, 1279-96	34
162	Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 3 months after myocardial infarction are more strongly associated with magnetic resonance-determined ejection fraction than NTproBNP levels in the acute phase. <b>2011</b> , 17, 479-86	7
161	Exercise-induced changes of B-type natriuretic peptide uncover the unknown coronary artery disease in patients with chest pain and normal left ventricular systolic function. <b>2011</b> , 18, 72-8	6
160	B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. <b>2011</b> , 167, 129-33	9

159	Establishing prognosis in heart failure: a multimarker approach. <b>2011</b> , 54, 86-96		38
158	Identification of cardiac dysfunction in sepsis with B-type natriuretic peptide. <b>2011</b> , 213, 139-46; discussion 146-7		47
157	[Mortality of myocardial infarction]. <b>2011</b> , 60, 311-6		7
156	Sensitivity and specificity of NT-proBNP to detect heart failure at post mortem examination. <b>2011</b> , 125, 849-56		14
155	Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. <b>2011</b> , 18, 135-43		30
154	Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis. <b>2011</b> , 4, 542		6
153	Clinical significance of elevated B-type natriuretic peptide in patients with acute lung injury with or without right ventricular dilatation: an observational cohort study. <b>2011</b> , 1, 18		12
152	B-type natriuretic peptide blood levels identify patients with non-ST elevation acute coronary syndromes at high risk for complications during intravenous beta-blocker infusion. <b>2011</b> , 13, 129-35		2
151	Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. <i>Circulation</i> , <b>2011</b> , 124, 1021-7	16.7	40
150	Increased B-type natriuretic Peptide concentration is associated with reduced coronary vasoreactivity in patients with dilated cardiomyopathy but not in healthy young subjects. <b>2011</b> , 2011, 638764		
149	Plasma Brain Natriuretic Peptide (BNP) as an Indicator of Left Ventricular Function, Early Outcome and Mechanical Complications after Acute Myocardial Infarction. <b>2011</b> , 5, 77-83		22
148	Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. <b>2012</b> , 302, R166-74		36
147	Deciphering the mechanisms of the Na <sup>+</sup> /H <sup>+</sup> exchanger-3 regulation in organ dysfunction. <b>2012</b> , 302, C1569-87		58
146	Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. <b>2012</b> , 123, 601-10		10
145	Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. <b>2012</b> , 58, 441-9		32
144	B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function. <b>2012</b> , 19, 366-73		8
143	N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial. <b>2012</b> , 14, 259-67		21
142	Serial measurements associated with an amelioration of acute heart failure: an analysis of repeated quantification of plasma BNP levels. <b>2012</b> , 1, 240-7		6

141 Twin-to-twin transfusion syndrome. 145-155

140 Prospective Validation of the Prognostic Usefulness of B-Type Natriuretic Peptide in Asymptomatic Patients With Chronic Severe Aortic Regurgitation. **2012**, 2012, 398-401

139 NT-ProBNP and cardiac troponin I in virulent canine babesiosis. **2012**, 190, 333-9

12

138 Intérêt et limites des biomarqueurs chez les patients avec décompensation de bronchopneumopathie chronique obstructive. **2012**, 217-229

137 Association of somatic and cognitive depressive symptoms and biomarkers in acute myocardial infarction: insights from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry. **2012**, 71, 22-9

13

136 Cardiovascular biomarkers and their utility in the older adult. **2012**, 6, 397-403

2

135 Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. **2012**, 109, 1117-23

11

134 Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF). **2012**, 59, 352-8

15

133 An amyloidogenic determinant in N-terminal pro-brain natriuretic peptide (NT-proBNP): Implications for cardiac amyloidoses. **2012**, 98, 67-75

9

132 Monitoring du choc cardiogénique. **2012**, 21, 412-417

131 Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. **2013**, 386, 665-70

19

130 Novel biomarkers for heart failure. **2013**, 11, 1155-69

18

129 Inflammatory activation is related to glucose impairment in diabetics with acute myocardial infarction. **2013**, 166, 533-6

1

128 Cardiac biomarkers in acute myocardial infarction. **2013**, 164, 282-94

76

127 B-type natriuretic peptide and infarct size in non-ST-elevation myocardial infarction. **2013**, 31, 1618

3

126 B-type natriuretic peptide and infarct size in ST-elevation myocardial infarction. **2013**, 31, 1619

4

125 Increased N-terminal CgA in circulation associated with cardiac reperfusion in pigs. **2013**, 7, 959-67

3

124 The potential role of natriuretic peptides in acute coronary syndrome stratification. **2013**, 9, 297-300

123	NT-proBNP levels in premenopausal women with polycystic ovarian syndrome and/or obesity. <b>2013</b> , 33, 868-72	3
122	BNP and NT-proBNP Assays for Heart-Failure Diagnosis in Patients With Cerebral Infarction. <b>2013</b> , 44, 46-50	4
121	Pericardial fluid and serum biomarkers equally predict ventricular dysfunction. <b>2013</b> , 21, 160-5	4
120	Cardiac troponin T and NT-proBNP as biomarkers of early myocardial damage in amitriptyline-induced cardiovascular toxicity in rats. <b>2013</b> , 32, 351-7	11
119	Preload reserve is restored in patients with decompensated chronic heart failure who respond to treatment. <b>2013</b> , 19, 207-13	1
118	Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy. <b>2013</b> , 20, 251-5	8
117	The plasma B-type natriuretic peptide levels are low in males with stable ischemic heart disease (IHD) compared to those observed in patients with non-IHD: a retrospective study. <b>2014</b> , 9, e108983	10
116	Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca(2+) release, and activation of protein kinase C. <b>2014</b> , 7, 75	30
115	Early defects identified by computed tomography angiography are associated with left ventricular dysfunction and exercise intolerance following acute myocardial infarction. <b>2014</b> , 32, 585-91	
114	The heart as an endocrine organ. <b>2014</b> , 3, R31-44	60
113	The increasing impact of a higher body mass index on the decrease in plasma B-type natriuretic peptide levels. <b>2014</b> , 4, 39-46	4
112	Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study. <b>2014</b> , 168, 931-9.e2	13
111	Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. <b>2014</b> , 44, 303-8	63
110	Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score. <b>2014</b> , 3, e001089	23
109	Dynamic use of B-type natriuretic peptide-guided acute coronary syndrome therapy. <b>2014</b> , 348, 283-7	2
108	Value of N-terminal pro brain natriuretic peptide in predicting prognosis and severity of coronary artery disease in acute coronary syndrome. <b>2014</b> , 26, 192-8	10
107	B-type natriuretic peptide levels predict extent and severity of coronary artery disease in non-ST elevation acute coronary syndrome and normal left ventricular function. <b>2014</b> , 66, 183-7	7
106	Beneficial neurohumoral profile in left ventricular systolic dysfunction following acute myocardial infarction. <b>2014</b> , 9, 64-73	



105	Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). <b>2014</b> , 63, 1644-53	64
104	Novel biomarkers in acute coronary syndromes: new molecules, new concepts, but what about new treatment strategies?. <b>2014</b> , 63, 1654-6	6
103	Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure. <b>2014</b> , 8, 493-497	
102	Borderline Values of Troponin-T and High Sensitivity C-Reactive Protein Did Not Predict 2-Year Mortality in TnT Positive Chest-Pain Patients, Whereas Brain Natriuretic Peptide Did. <b>2015</b> , 2, 16	1
101	Elevated Plasma IL-38 Concentrations in Patients with Acute ST-Segment Elevation Myocardial Infarction and Their Dynamics after Reperfusion Treatment. <b>2015</b> , 2015, 490120	23
100	The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. <b>2015</b> , 65, 121-7	39
99	Efficacy of positive airway pressure on brain natriuretic peptide in patients with heart failure and sleep-disorder breathing: a meta-analysis of randomized controlled trials. <b>2015</b> , 193, 255-60	8
98	Cardiovascular Biomarker Assessment Across Glycemic Status. <b>2015</b> , 245-268	0
97	4,4RMethylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats. <b>2015</b> , 147, 235-45	4
96	Wnt10b Gain-of-Function Improves Cardiac Repair by Arteriole Formation and Attenuation of Fibrosis. <b>2015</b> , 117, 804-16	43
95	MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. <b>2015</b> , 22, 693-700	22
94	Plasma B-type natriuretic peptide levels are poorly related to the occurrence of ischemia or ventricular arrhythmias during symptom-limited exercise in low-risk patients. <b>2016</b> , 12, 341-8	2
93	Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. <b>2016</b> , 32, 1470-1477	2
92	MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure. <b>2016</b> , 20, 1287-1300	9
91	Fetal cardiovascular hemodynamics in twin-twin transfusion syndrome. <b>2016</b> , 95, 664-71	21
90	Prognostic Utility of Brain Natriuretic Peptide in Asymptomatic Patients With Significant Mitral Regurgitation and Preserved Left Ventricular Ejection Fraction. <b>2016</b> , 117, 258-63	17
89	2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers. <b>2016</b> , 35, 284-93	10
88	Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. <b>2016</b> , 111, 2	59

87	Multiphasic Regulation of Systemic and Peripheral Organ Metabolic Responses to Cardiac Hypertrophy. <b>2017</b> , 10,	7
86	Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction. <b>2017</b> , 7, 44168	7
85	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <b>2017</b> , 6,	45
84	State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. <b>2017</b> , 63, 165-176	26
83	[What is the place for biomarkers during acute COPD exacerbations?]. <b>2017</b> , 34, 382-394	
82	N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure. <b>2017</b> , 33, 1478-1488 <sup>14</sup>	
81	Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. <b>2017</b> , 6,	42
80	A Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1 $\beta$ Secretion via Downregulation of NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 Activation in Human THP-1 Monocyte. <b>2017</b> , 2017, 5858315	31
79	B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction. <b>2018</b> , 200, 37-43	4
78	Evolving Role of Natriuretic Peptides from Diagnostic Tool to Therapeutic Modality. <b>2018</b> , 1067, 109-131	8
77	Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension. <b>2018</b> , 196, 315-319	5
76	Is B-type natriuretic peptide (BNP) similarly associated with mortality in patients with and without heart failure?. <b>2018</b> , 6, S9	1
75	Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation. <b>2018</b> , 46, 5183-5194	8
74	Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). <b>2018</b> , 2018, 9542784	3
73	Misconceptions in acute heart failure diagnosis and Management in the Emergency Department. <b>2018</b> , 36, 1666-1673	2
72	Tongguan Capsule Mitigates Post-myocardial Infarction Remodeling by Promoting Autophagy and Inhibiting Apoptosis: Role of Sirt1. <b>2018</b> , 9, 589	15
71	B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. <b>2018</b> , 71, 2079-2088	58
70	Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes. <b>2018</b> , 9, 855	5

69	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. <b>2020</b> , 41, 882-889	11
68	Twin-to-Twin Transfusion Syndrome: Placental and Fetal Pathogenesis. <b>2019</b> , 344-352	
67	Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. <b>2019</b> , 216, 62-73	3
66	Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. <b>2019</b> , 20,	12
65	Short-term follow-up BNP level and risk stratification after myocardial infarction. <b>2019</b> , 291, 173-174	3
64	Serum BNP levels are associated with malignant pericardial effusion. <b>2019</b> , 23, 100359	1
63	BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. <b>2019</b> , 20,	76
62	Biomarker panel in sleep apnea patients after an acute coronary event. <b>2019</b> , 68, 24-29	1
61	Novel biomarkers of cardiovascular disease: Applications in clinical practice. <b>2019</b> , 56, 33-60	37
60	Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. <b>2019</b> , 8, 643-651	9
59	Evaluation of Agonal Cardiac Function for Sudden Cardiac Death in Forensic Medicine with Postmortem Brain Natriuretic Peptide (BNP) and NT-proBNP: A Meta-analysis. <b>2020</b> , 65, 686-691	5
58	Role of N-terminal pro-B-type natriuretic peptide in the prediction of outcomes in ST-elevation myocardial infarction complicated by cardiogenic shock. <b>2020</b> , 72, 302-305	3
57	Artificial Intelligence Uncovered Clinical Factors for Cardiovascular Events in Myocardial Infarction Patients with Glucose Intolerance. <b>2020</b> , 34, 535-545	1
56	Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels. <b>2020</b> , 7, e001200	1
55	Mitral regurgitation: lessons learned from COAPT and MITRA-Fr. <b>2020</b> , 12, 2936-2944	4
54	Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance. <b>2020</b> , 34, 79-88	1
53	Rho-Kinase inhibitors ameliorate diclofenac-induced cardiotoxicity in chloroquine-treated adjuvant arthritic rats. <b>2020</b> , 254, 117605	5
52	Peripheral Blood RNAs and Left Ventricular Dysfunction after Myocardial Infarction: Towards Translation into Clinical Practice. <b>2021</b> , 14, 213-221	1

51	Using models to advance medicine: mathematical modeling of post-myocardial infarction left ventricular remodeling. <b>2021</b> , 1-10	
50	Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis. <b>2021</b> , 12, 693099	3
49	Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives. <b>2021</b> , 22,	6
48	Recent advances in the understanding of water metabolism in heart failure. <b>1998</b> , 449, 415-26	34
47	Physiology of Natriuretic Peptides and Their Receptors. <b>2007</b> , 277-305	1
46	Brain natriuretic peptide: role in cardiovascular and volume homeostasis. <b>2002</b> , 22, 423-37	15
45	N-3 Fatty Acids and Cardiac Function after Myocardial Infarction in Denmark. <b>2001</b> , 60, 360-365	3
44	B-Type Natriuretic Peptide Is Associated with Indices of Left Ventricular Dysfunction in Healthy Subjects from the General Population: The Akershus Cardiac Examination 1950 Study. <b>2021</b> , 67, 204-215	2
43	Neurohormonal markers of clinical outcome in cardiovascular disease: is endothelin the best one?. <b>1998</b> , 32 Suppl 2, S36-42	8
42	Neurohormonal Markers of Clinical Outcome in Cardiovascular Disease. <b>1998</b> , 32, S36-S42	43
41	Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. <b>2002</b> , 25, 669-76	42
40	Do optimal prognostic thresholds in continuous physiological variables really exist? Analysis of origin of apparent thresholds, with systematic review for peak oxygen consumption, ejection fraction and BNP. <b>2014</b> , 9, e81699	19
39	Volumetric Response beyond Six Months of Cardiac Resynchronization Therapy and Clinical Outcome. <b>2015</b> , 10, e0124323	8
38	Relationship between the plasma levels of brain natriuretic peptide and left ventricular ejection fraction in asymptomatic patients with previous myocardial infarction. <b>2005</b> , 46, 1007-14	6
37	The benefits of repeated measurements of B-type natriuretic peptide in patients with first ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. <b>2006</b> , 47, 843-54	3
36	Usefulness of the percentage of plasma lymphocytes as a prognostic marker in patients with congestive heart failure. <b>2004</b> , 45, 275-84	12
35	Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. <b>2001</b> , 12, 1508-1515	225
34	Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. <b>2005</b> , 20, 26-32	12



15	Clinical Considerations and Applications in Cardiac Diseases. <b>2006</b> , 91-132			1
14	B-TYPE NATRIURETIC PEPTIDE(BNP) LEVELS AND ITS PROGNOSTIC VALUE IN ACUTE CORONARY SYNDROMES(ACS). <b>2020</b> , 27-29			
13	The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. <i>Biomarker Insights</i> , <b>2007</b> , 1, 143-55		3.5	
12	B-Type Natriuretic Peptide (BNP) and Left Ventricular (LV) Function in Patients with ST-Segment Elevation Myocardial Infarction (STEMI). <i>Medica</i> , <b>2010</b> , 5, 243-9			1
11	Cutoff Value of Admission N-Terminal Pro-Brain Natriuretic Peptide Which Predicts Poor Myocardial Perfusion after Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. <i>Acta Cardiologica Sinica</i> , <b>2016</b> , 32, 649-655	1.1		2
10	Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications. <i>Journal of Atrial Fibrillation</i> , <b>2009</b> , 2, 125	0.8		4
9	Pathogenesis of CoViD19 Miscellaneous Mechanisms. <b>2022</b> , 183-215			
8	Table_1.DOCX. <b>2018</b> ,			
7	Image_1.tif. <b>2018</b> ,			
6	Table_1.DOC. <b>2018</b> ,			
5	Table_2.DOC. <b>2018</b> ,			
4	Impact of Exercise-Induced Pulmonary Hypertension on Right Ventricular Function and on Worsening of Cardiovascular Risk in HIV Patients. <b>2022</b> , 11, 7349			0
3	Endocrine functions of the heart: from bench to bedside.			2
2	EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM.			0
1	Increased levels of NT-proBNP and troponin T 2 years after coronary artery bypass grafting complicated by mediastinitis. 10,			0